TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A retrospective review of 60 psychiatric patients found that symptom scores improved after L-methylfolate was added to existing treatment, with the largest measured change in executive function. The non-randomized study cannot show that L-methylfolate caused the gains, and the authors said controlled research is needed.
A retrospective chart review of 60 psychiatric patients found that symptom scores improved after L-methylfolate was added to existing treatment, with the largest measured gain in executive function. The results, presented at the Neuroscience Education Institute (NEI) Fall Congress, show an association in routine clinical practice, not proof that the supplement caused the changes.
Researchers reviewed records from 2021 to 2026, comparing patients’ scores before and during L-methylfolate treatment. Of 131 identified charts involving Deplin, 60 patients had visits in both periods and formed the analysis group. The team used a within-patient interrupted time-series approach and combined scores from the ASSET, PHQ-9 and GAD-7 scales to assess overall symptom burden.
The pooled analysis found an average treatment effect on the treated of -0.14 standard deviations (95% confidence interval, -0.20 to -0.08; P<0.0001). Individual measures also improved: executive-function scores on the ASSET (n=58) had a paired effect size of -0.50; depression scores on the PHQ-9 (n=60), -0.30; and anxiety scores on the GAD-7 (n=28), -0.39. The GAD-7 was added to the clinic’s surveys in late 2024, leaving fewer records for that measure.
The authors also reported that improvement was more pronounced among patients who had tried more medication classes before starting L-methylfolate. Each additional prior medication class was associated with 0.118 standard deviations of greater symptom improvement in a mixed-model analysis (P=0.005). This is an observed relationship, not evidence that prior medication use predicts an individual patient’s response.
Executive Function Showed the Largest Change
The results address a practical question for clinicians: whether patients with persistent symptoms might show changes in areas beyond mood after an add-on treatment. In this chart review, executive-function scores had the largest measured improvement, while depression and anxiety scores also moved in a favorable direction. The pattern may help shape future research into outcomes patients experience in everyday life.
However, score changes do not by themselves establish that patients had meaningful improvements in daily functioning, nor do they show which patients are likely to benefit. The study’s exploratory analysis of 23 stimulant-treated patients found a change in dose trajectories after L-methylfolate initiation, but this was outside the product’s approved dietary-management labeling and does not establish that L-methylfolate reduces stimulant requirements. It should not be treated as prescribing guidance.
Products Worth Considering
Fitbit Sense 2 Health and Fitness Smartwatch, Shadow Grey/Graphite
Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale
Garmin Forerunner 935 GPS Running and Multisport Watch, Black
As an affiliate, we earn on qualifying purchases.
How the Clinic Review Was Conducted
L-methylfolate is the biologically active form of folate, or vitamin B9. The source report describes Deplin as a prescription medical food for the dietary management of suboptimal folate levels in patients with depression and schizophrenia, intended for use under medical supervision. The researchers said its added benefit alongside standard psychiatric treatment, particularly among treatment-experienced patients in routine practice, had not been well characterized.
Earlier clinical research has reported benefits from adjunctive L-methylfolate for some patients whose depression responded incompletely to standard antidepressants, according to the source report. The new analysis broadened the outcomes examined to include anxiety and executive function. Its cohort was demographically limited: the report described it as 97.7% white and 1.5% Hispanic or Latino, which constrains how readily the findings can be applied to other populations.
“What caught my attention most was the pattern of improvement: patients’ executive-function scores showed the largest and earliest change, with depression and anxiety improving more gradually.”
— Richard Powell, PhD, JD, co-author, speaking to MedPage Today
Causation and Patient Benefit Remain Unclear
The review was observational and non-randomized, with no comparison group described in the report. The authors said regression to the mean—symptoms improving after treatment begins during a period of active symptoms—could explain some of the change. Confounding by indication and adjustments to other medications during the study period also cannot be ruled out.
All reported P-values were nominal and were not adjusted for multiple comparisons. The anxiety result came from a smaller sample than the depression and executive-function results, and the cohort’s demographic profile limits generalizability. The analysis therefore does not establish how much improvement, if any, was attributable specifically to L-methylfolate, whether score changes translated into daily-life benefits, or how results compare with those from patients who did not receive it.
Controlled Studies Are the Next Step
The authors called for controlled research to separate the effect of L-methylfolate from other explanations for the score changes. Future work would need to clarify which patients, if any, benefit, whether improvements extend to everyday functioning, and how the treatment performs alongside different psychiatric regimens. The available report does not specify a planned trial or timeline.
For now, these findings are best read as an observational signal from one clinical record review, not as evidence that L-methylfolate is effective for every patient or a substitute for established care. Powell said clinicians should continue asking about persistent symptoms and day-to-day functioning, while decisions about treatment remain matters for patients and qualified health professionals.
Key Questions
What did the study find?
In a review of 60 patients, symptom scores improved after L-methylfolate was added to existing psychiatric treatment. Executive-function scores showed the largest measured change, followed by depression and anxiety scores.
Does the study prove L-methylfolate caused the improvements?
No. The review was observational and non-randomized, so other explanations—including changes to other treatments and regression to the mean—cannot be ruled out.
How many patients were included in each measure?
The analysis included 58 patients for executive function, 60 for depression and 28 for anxiety. The anxiety measure had a smaller sample because the clinic added the GAD-7 survey in late 2024.
What is needed to confirm the findings?
The study authors said controlled research is needed to estimate how much of the observed improvement was attributable to L-methylfolate and whether score changes correspond to meaningful improvements in daily life.
Source: medpagetoday.com
